Altered sphingolipid metabolism in patients with metastatic pancreatic cancer

Keyphrases

• Sphingolipid Metabolism 100%
• Pancreatic Cancer 100%
• Metastatic Pancreatic Cancer 100%
• Cancer Patients 75%
• Sphingolipids 75%
• Lymph Node Metastasis 50%
• Human Pancreatic Cancer 50%
• Positive Lymph Nodes 50%
• IP-10 50%
• Nodal Disease 50%
• Lipids 25%
• Interleukin-6 25%
• Clinical Setting 25%
• Growth Factors 25%
• Ceramide 25%
• Pancreas 25%
• Tumor Specimens 25%
• Proteomic Analysis 25%
• Cytokine Levels 25%
• Risk Stratification 25%
• Patient Samples 25%
• Plasma Parameters 25%
• Genetic mutation 25%
• Sphingosine-1-phosphate 25%
• Pancreatitis 25%
• Interleukin-8 25%
• Advanced Disease 25%
• Sphingosine 25%
• Whole Genome Amplification 25%
• Pancreatic Tumor 25%
• Transcriptome Analysis 25%
• Subgroup Analysis 25%
• Cancer Tumor 25%
• Cytokine Factors 25%
• Cerebroside 25%
• CXCL10 25%
• CCL11 25%
• Molecular Pathogenesis 25%
• Lipid Analysis 25%
• Ceramide Species 25%
• Eotaxin 25%
• Interferon-inducible Protein 10 25%

Biochemistry, Genetics and Molecular Biology

• Sphingolipid Metabolism 100%
• Sphingolipid 100%
• Blood Plasma 100%
• Lipidomics 66%
• Ceramide 66%
• Cytokine 33%
• Mass Spectrometry 33%
• Lipid 33%
• Metabolite 33%
• Growth Factor 33%
• Gene Expression Profiling 33%
• Gene Mutation 33%
• Blood Level 33%
• Interleukin 6 33%
• Sphingosine 33%
• Interleukin 8 33%
• CXCL10 33%
• Interferon 33%
• Proteomics 33%
• Cerebroside 33%
• Eotaxin 33%
• CCL11 33%

Immunology and Microbiology

• Blood Plasma 100%
• Sphingolipid Metabolism 100%
• Lymph Node 66%
• Metabolite 33%
• Growth Factor 33%
• Gene Mutation 33%
• Blood Level 33%
• Pancreas 33%
• Cytokine 33%
• Pancreatitis 33%
• Mass Spectrometry 33%
• Interleukin 6 33%
• CCL11 33%
• Eotaxin 33%
• CXCL10 33%
• Gene Expression Assay 33%
• Interleukin 8 33%
• Proteomics 33%
• Gamma Interferon Inducible Protein 10 33%